Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.33 |
| ▸ | PER2 | O15055 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366998 | 0.89 | CYP2C9 (0.90) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL5089690 | 0.83 | CYP2C9 (1.00) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6687554 | 0.82 | CYP2C9 (0.79) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL7077857 | 0.81 | CYP2C9 (0.78) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6690316 | 0.79 | CYP2C9 (0.83) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6693467 | 0.79 | CYP2C9 (0.79) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6686262 | 0.79 | CYP2C9 (0.67) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6693468 | 0.79 | CYP2C9 (0.81) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6232054 | 0.78 | CYP2C9 (0.80) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL7131813 | 0.78 | CYP2C9 (0.80) | CYP2C9NR1I2MAPK1HSD17B10PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070274951-A1 | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070274951-A1 | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| WO-2007092616-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070274951-A1 | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto | PREP, CTRL, SERPINB1 | CYP2C9 2224/4885NR1I2 2880/4885MAPK1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.